The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for Metformin Hydrochloride, effective 2026-06-26. This revision highlights postmarketing cases of metformin-associated lactic acidosis, which have resulted in severe outcomes including death, hypothermia, hypotension, and resistant bradyarrhythmias. The updated warning notes that the onset of this condition is often subtle.
Background
The label revision pertains to Metformin Hydrochloride, a drug associated with the risk of lactic acidosis. This condition has been observed in postmarketing cases.
What this means
The revision of the boxed warning for Metformin Hydrochloride underscores the serious risks associated with metformin-associated lactic acidosis. Healthcare professionals should be aware of the updated label information, particularly regarding the potential for death, hypothermia, hypotension, and resistant bradyarrhythmias, and the often subtle onset of this adverse event. This update emphasizes the importance of vigilance in monitoring patients receiving Metformin Hydrochloride.
Source
The U.S. Food and Drug Administration (FDA) revised the label for Metformin Hydrochloride on 2026-06-26. The updated information is available on the DailyMed website (dailymed.nlm.nih.gov), an official database of drug labels.